Ace the Case: Disease Progression in a 72-Year-Old Woman With Chronic Lymphocytic Leukemia Previously Treated With Venetoclax-Obinutuzumab
This activity is supported by independent educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and TG Therapeutics, Inc.
Click Here to Manage Email Alerts
Release date: February 23, 2022
Expiration date: February 23, 2023
Estimated time to complete: 30 minutes
This continuing medical education activity is jointly provided by
This activity utilizes a case study to discuss treatment options for an older patient with relapsed chronic lymphocytic leukemia (CLL).
This activity has been designed to meet the educational needs of hematologists, oncologists, and other health care professionals involved in the management of patients with CLL.
Upon completion of this activity, participants should be better able to (1) identify the safety profiles of the novel targeted agents used to treat CLL; (2) outline treatment adjustments based on current and emerging data to effectively mitigate adverse events while still achieving the deepest and most durable response.
Online case-based activity
Chaitra S. Ujjani, MD
University of Washington/Fred Hutchinson Cancer Research Center
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RedMedEd. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 ABIM MOC Part 2 credit MOC points in the ABIM’s MOC program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Additional information will be collected from those claiming MOC credit, including but not necessarily limited to their ABIM registration number and birthdate (mm/dd). MOC participant data will be uploaded to the ACCME PARS system by Postgraduate Institute for Medicine, which will automatically transmit the data to ABIM.
How to Participate in This Activity and Obtain CME Credit
There are no fees for participating and receiving credit for this activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit, participants must complete the posttest and program evaluation. Certificates can be printed immediately.
Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high-quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Chaitra S. Ujjani, MD,has disclosed the following relevant financial relationships:
Consultant: AbbVie, AstraZeneca, Atara Biotherapeutics, ADC Therapeutics, Epizyme, Janssen, MorphoSys, Pharmacyclics, TG Therapeutics
Contracted Research: AbbVie, AstraZeneca, Adaptive Biotechnologies, Gilead, LOXO/Lilly, Pharmacyclics
Postgraduate Institute for Medicine
The Postgraduate Institute for Medicine planners and others have nothing to disclose.
The RedMedEd planners and others have nothing to disclose.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine; RedMedEd; AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and TG Therapeutics, Inc. do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
If you have questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine via email at firstname.lastname@example.org.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or email@example.com.
A computer, Apple iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection using one of these browsers: Chrome, Firefox, Safari, Microsoft Edge
CME credit for this activity is provided by Postgraduate Institute for Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Postgraduate Institute for Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Postgraduate Institute for Medicine or RedMedEd may use the information you provide on this site to contact you about your CME credit or other relevant educational activities. For more information, contact firstname.lastname@example.org or email@example.com.
© 2022. This CME-certified program is held as copyrighted by Postgraduate Institute for Medicine and RedMedEd. Through this notice, Postgraduate Institute for Medicine and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.